This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
startups raised half a billion dollars apiece, and another eight raised $100 million or more, with industries from cybersecurity to biotech to AI represented. and AI product development. The latest startup in the space to get a big chunk of cash is Beta Technologies, maker of electric vertical take-off and landing planes.
From AI models that boost sales to robots that slash production costs, advanced technologies are transforming both top-line growth and bottom-line efficiency. Business leaders dont need to be technology experts to grasp this shift; they need vision and urgency. Crucially, the time and cost to implement AI have fallen.
That’s why we weren’t very surprised when a slew of investors told us they rarely see a biotech startup that doesn’t incorporate AI in some form or other these days. But despite becoming quite the buzzword, AI’s apparent ubiquity in biotech isn’t actually driving deal flow or higher valuations.
2021 should be a banner year for biotech startups that make smart choices early. After a record year for biotech investment in 2020 — during which the industry saw $28.5 Since 1996 , 14,000 startups have licensed technology out of those universities, and 67% of licenses were taken by startups or small companies. Kevin O’Connor.
Biotech offerings, while more plentiful, are also running well below prior highs. Below, we pick out winners and losers for venture-backed tech and biotech companies, focusing on large- and medium-sized IPOs. The provider of AI and cloud connectivity technology was recently valued around $18 billion. Just a handful of U.S.
Given this success, many biotech companies are looking to move on to the next phase of their organizational growth — which may mean an initial public offering. As optimism grows, market conditions may stabilize in 2025 — particularly in the wake of the recent interest rate cuts — and more biotech companies may consider offerings.
Omar Khalil is a partner at Santé Ventures , where he focuses primarily on biotechnology and medical technology companies. Capital is the fuel that advances scientific and technological innovation, and it means a life science startup can create products that benefit the world at large. Omar Khalil. Contributor. Share on Twitter.
Stämm Biotech , founded in 2014, is developing a desktop-sized bioreactor that looks pretty different from the tanks, tubes and knobs traditionally seen in industrial or even benchtop bioreactors. Instead, it’s developing a unit that 3D prints a dense network of microchannels that pass cells through the nutrients and oxygen they need.
With the constant advancements in technology and research, businesses in this sector require leaders who possess a deep understanding of the scientific landscape and the business acumen to drive growth and innovation. The life sciences industry is known for its unique challenges in recruiting and hiring.
Biotech can often, and sometimes literally, fly over our heads. For IndieBio, a science and biotech accelerator run by VC firm SOSV, this unprecedented year offered high stakes and new challenges. Today and tomorrow, the biotech accelerator is hosting its twice-annual demo day.
Lambda is also a provider of the latest GPUs by Nvidia , which are highly sought after by AI developers. Eikon Therapeutics , $351M, biotech: Eikon Therapeutics raised one of the biggest biotech rounds thus far in 2025. Harvey develops AI tools that help legal pros with research, document review and contract analysis.
“As your technology becomes more dated, you too will have to make similar decisions.” 6 questions investors should ask when evaluating psychedelic biotech companies. 6 questions investors should ask when evaluating psychedelic biotech companies. . ” Thanks very much for reading — have a great weekend!
Improving the diversity of global genomic data could hasten medical breakthroughs — and that’s the goal of Gen-t , a Brazilian startup working to infuse biotech with genetic data from the country’s population.
Atarraya , creator of Shrimpbox, a sustainable “plug-and-play” shrimp farming technology, is swimming to the surface after being in stealth mode since 2019. That grew into aquaculture farming technology with Russek and his team creating a startup company around it called Maricultura Vigas. million in Series A dollars, and a new U.S.
billion globally went to companies applying advances in artificial intelligence to health-related areas such as medical services and pharmaceutical development, per Crunchbase data. Alto Neuroscience , developer of a machine learning-driven precision treatment platform for psychiatric care, has also underperformed.
In August, San Francisco-based Magic , which also develops AI models to write software, raised a $320 million round, and AI-powered coding assistant Codeium closed a $150 million Series C. The company is developing advanced small modular nuclear reactors for clean energy generation. Rowe Price.
By Caleb Appleton Having invested in the biotech space since before it had a name, Ive seen life sciences investors steer founders toward a therapeutics pipeline in hopes of securing the payout of a winning drug or medical device. Is there a business model to support the technology?
Sifting through the trillions of molecules out there that might have powerful medicinal effects is a daunting task, but the solution biotech has found is to work smarter, not harder. Machine learning has, of course, accelerated work in many fields, biochemistry among them, but he felt that the potential of the technology had not been tapped.
Peter Gajdoš is a partner at Fifth Wall , where he co-leads the Climate Technology Investment team. So what do we do about it, and how do we allocate our money, time and brainpower to develop solutions? I believe it is a financial and a moral imperative to make climate technology, together with medicine, the main priority of humanity.
Multidomain integration is becoming a cornerstone of modern software development, bridging technologies like blockchain, biotech, and consumer applications. These cross-domain projects are no longer optional they are the future of innovation. However, combining such diverse systems presents unique challenges.
To a great degree, the largest rounds of the year went to a handful of AI companies working on large language models and underlying technologies to scale them. While the Boston startup scene is famous for biotech and deeptech talent, the city has lagged other hubs in creation of ultra-high-valuation AI unicorns. billion in all of 2023.
Venture money wasnt concentrated in just one sector, as VCs invested in everything from artificial intelligence to biotech to energy. The Norwalk, Connecticut-based firm did not disclose investor names, instead saying it came from a private investor whose portfolio focuses on global technology and real estate investments.
Just three years after its founding, biotech startup Immunai has raised $60 million in Series A funding, bringing its total raised to over $80 million. ” Mission Bio raises $70 million to help scale its tech for improving the development of targeted cancer therapies. ’,” said Solomon.
ahin, his wife and co-founder Özlem Türeci, and the rest of the seven-person founding team began their research. “At that time, mRNA was not potent enough,” ?
When I started at Novanta about five years ago, my first mission was to bring scalability to our Enterprise solutions, as well as developing a digital roadmap to modernize the technology footprint, reduce technical debt, and explore strategies to ensure that we’re growing at scale. We need more women in technology.
Protein biochemist Dr. Jasmin Hume was working in the alternative food space when she saw an opportunity to evolve technology so that our global food industry can reduce its reliance on animals. She started Shiru in 2019, and the company uses a “precision fermentation” process to create plant-based ingredients for food companies.
The week was especially good for biotech, which led the way with two big raises. Tome Biosciences , $213M, biotech: A big biotech raise hit high on the list this week. The company plans to use the tech to develop gene therapies for monogenic liver diseases and cell therapies for autoimmune diseases.
Biotech/healthcare and cybersecurity dominated the run of big rounds this week, with a few AI startups also seeing good-sized checks. Marea Therapeutics , $190M, biotech: This big biotech round is actually the combination of two rounds. The top five raises this week came from sectors that have seen good heat recently.
Wonder ’s big $700 million raise may have captured most people’s attention last month, but the story when it came for large deals was really biotech. That makes it quite the month for startups looking to develop drugs and therapies for all that ails us. That sector saw seven of the rounds on this list. billion, per Crunchbase.
Of course, biotech and fintech were in there too. tied) Serán Bioscience , $200M, biotech : The big biotech raise this week went to Serán Bioscience. The company will use the fresh capital to support product development, including the launch of flight and rental car bookings to its platform.
According to a statement, the company will invest heavily in developing new manufacturing technologies across cell and gene therapies, viral vectors, vaccines and proteins. billion to spend on sustainability and health-focused biotech. “It Founded by ARCH Venture Partners investor Robert Nelsen, National Resilience Inc.,
Based in Japan, biotech startup Dioseve ’s ambitious goal is to grow human oocytes, or eggs, from other tissue. Dioseve’s mission might sound like it comes out of science fiction, but it’s based on a scientific technique called induced pluripotent cells stem (iPS) cells, which was first developed in 2006.
Nerdio , $500M, information technology: IT professionals are stretched pretty thin these days, so it makes sense that a company that helps automate some of their work could raise big. Latigo Biotherapeutics , $150M, biotech: Many patients shy away from taking opioids while many doctors are reluctant to prescribe the painkillers.
Italy’s ecosystem for tech venture capital and startups has been in development for years and has made decent strides in the last decade. And Apple has sponsored a Naples-based developer academy. Will the coronavirus stymie their efforts? Microsoft has announced a $1.5 NTT data is investing in Calabria.
Technologists are getting better at coding biology and venture firms are flooding a new generation of startups with cash so they can commercialize their technology bringing in the next wave of genetic innovation. The ability to write in the code of life will be a defining technology of this century and drive a fundamental change in medicine.
A prominent figure in life sciences innovation, Imran has founded over 20 medical device companies and helped develop the world’s first implantable cardiac defibrillator. The technology itself started with a very simple thesis,” said Imran in an interview. This will finance us for the next several years,” said Imran.
But despite reaching a $10 billion valuation and spending over a decade in development, Theranos’ technology never actually worked, and in the most egregious cases, patients were presented with dangerously false medical results. This story is developing… What’s left to learn from Theranos? Have friends.
AgBiome , developing products from microbial communities, brought in a $116 million Series D round as the company prepares to pad its pipeline with new products. The company, based in Research Triangle Park, N.C., was co-founded in 2012 by a group including co-CEOs Scott Uknes and Eric Ward, who have known each other for over 30 years.
Planted appeared in 2019 as a spinoff from Swiss research university ETH Zurich, where the founders developed the original technique of extruding plant proteins and water into fibrous structures similar to real meat’s. Over time the process has improved as well. Over time the process has improved as well.
Startups developing so-called deep tech often find it challenging to raise capital for various reasons. Pae Wu and Garrett Winther are both partners at SOSV and run the fund’s programs around biotech and hardware. Pae Wu and Garrett Winther are both partners at SOSV and run the fund’s programs around biotech and hardware.
Physical Intelligence , $400M, robotics: Physical Intelligence, a startup developing brains for a wide array of robots, raised a $400 million round at a $2 billion valuation led by Jeff Bezos , Lux Capital and Thrive Capital , per The New York Times. So instead of running a list of 10, we’re going with a top five. Investors were not named.
The Importance of Executive Search and Leadership Development to the Growth of the Life Sciences Industry Ensuring that organizations have access to top talent for key leadership positions and that talent is sufficiently supported and developed is critical to the growth of the life sciences industry.
Respira Labs , a medical technology company specializing in respiratory care, which first unveiled its product to the world last year , successfully raised $1 million in funding and an additional $1.8 million in grants to continue building its acoustic resonance technology to assess lung function and changes therein.
Its a good time to be an AI chip developer. Early last year, application security developer Snyk reported it grew its revenue by 50% to $220 million in 2023, while also cutting its losses by 33%, according to the companys Directors Report filed with the U.K.s Nevertheless, it seems almost certain to go public soon. Companies House.
We organize all of the trending information in your field so you don't have to. Join 49,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content